Company intelligence / Profile preview
SAB BIO
Miami Beach, Florida, United Statessab.bio ↗
- Ownership
- Public · SABS
- Employees
- ~75
- Development stage
- Phase 1
01
Overview
SAB BIO’s lead candidate, SAB-142—a fully human anti-thymocyte immunoglobulin—has shown positive topline results in Phase 1 trials for type 1 diabetes. The therapy aims to delay onset and progression of T1D by modulating the immune response that destroys insulin-producing beta cells. Unlike rabbit-derived ATG therapies that can cause serum sickness and anti-drug antibodies in humans, the human origin of SAB‑142 may allow safer repeat dosing without these adverse effects. Across seven clinical trials with over 700 participants dosed with various assets from their platform, no cases of serum sickness or neutralizing anti-drug antibodies have been reported
- Therapeutic areas
- EndocrinologyInfectious Diseases
- Modalities
- Human polyclonal immunoglobulins (IgGs), specifically human anti-thymocyte immunoglobulin (hIgG)
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
BARDA funding for previous programs targeting infectious diseases such as influenza and emerging pathogensacademic collaborations with University of South Dakota Discovery District as an anchor tenant
04
Financials
- Market cap
- $316.6M
- Total revenue
- $0
- Enterprise value
- $219.1M
Beyond the preview
Go deeper on SAB BIO.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAB BIO.